Full Breakdown
FDA Reverses Course on Moderna's mRNA Flu Vaccine
2/20/2026, 3:57:24 AM
FDA's Decision to Review Moderna's Vaccine
On February 18, 2026, the U.S. Food and Drug Administration (FDA) announced it would review Moderna's experimental mRNA influenza vaccine, reversing its previous decision to reject the application. This unexpected change followed a week after the FDA had expressed concerns regarding the design of Moderna's clinical trials, particularly the lack of a higher-strength flu vaccine in the control group for older adults. In response, Moderna modified its application to address these concerns.
Details of the Application
Moderna is now seeking full approval for its vaccine for adults aged 50 to 64 and accelerated approval for those aged 65 and older. The accelerated approval pathway allows the vaccine to reach the market more quickly based on preliminary data, while additional studies will be conducted post-marketing to monitor its effectiveness in older populations. If approved, this would mark the first flu vaccine utilizing mRNA technology, which gained prominence during the COVID-19 pandemic.
Implications of the Reversal
The FDA's decision to review the vaccine has significant implications for both public health and Moderna's business strategy. The agency is expected to make a final decision by August 5, 2026, allowing for distribution in time for the upcoming flu season. Moderna's CEO, Stéphane Bancel, expressed optimism about the vaccine's potential to provide a new protective option for seniors against influenza.
Criticism and Opposition
The reversal has not been without controversy. Health Secretary Robert F. Kennedy Jr., a known critic of mRNA vaccines, has previously raised concerns about their safety and efficacy. His administration has implemented sweeping changes to U.S. immunization policies, including a reduction in funding for mRNA vaccine development. Critics argue that the FDA's initial refusal to review Moderna's application was justified, citing the need for a higher-strength vaccine in trials for older adults. HHS spokesperson Andrew Nixon emphasized that Moderna's study design did not adhere to FDA guidance, potentially exposing older participants to increased risks.
Conflicting Reports & Gaps
While Moderna contends that its trial design was consistent with FDA guidance prior to the study, the FDA's refusal to review the application indicates a significant disagreement over the standards for clinical trials. The FDA has not identified any safety or efficacy concerns with the vaccine itself, but the agency's insistence on a higher-strength comparator has raised questions about the regulatory landscape for mRNA vaccines.
Verbatim Quotes
“Pending FDA approval, we look forward to making our flu vaccine available later this year so that America’s seniors have access to a new option to protect themselves against flu.” — Stéphane Bancel, CEO of Moderna
“We appreciate the FDA’s engagement in a constructive Type A meeting and its agreement to advance our application for review,” — Stéphane Bancel, CEO of Moderna
“The most protective flu shots for seniors are a subset of high dose flu shots recommended by the CDC Advisory Committee on Immunization Practices, which would have served as the proper control in this study,” — Andrew Nixon, HHS Spokesperson
What's Next
As the FDA prepares to review Moderna's application, the outcome will not only affect the company's future in the vaccine market but also shape public health strategies regarding influenza vaccination, particularly for older adults. The decision is anticipated to have broader implications for the acceptance and use of mRNA technology in vaccines moving forward.
